47,215 Shares of The Cooper Companies, Inc. $COO Purchased by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. purchased a new stake in The Cooper Companies, Inc. (NASDAQ:COO) during the 3rd quarter, Holdings Channel reports. The firm purchased 47,215 shares of the medical device company’s stock, valued at approximately $2,669,000.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Cooper Companies during the 2nd quarter worth approximately $1,077,762,000. Generation Investment Management LLP purchased a new stake in Cooper Companies in the 2nd quarter valued at approximately $356,304,000. Jupiter Topco LLC purchased a new stake in Cooper Companies in the 2nd quarter valued at approximately $305,074,000. Bank of America Corp DE acquired a new stake in Cooper Companies during the 2nd quarter valued at $144,125,000. Finally, Manning & Napier Advisors LLC acquired a new stake in Cooper Companies during the 2nd quarter valued at $107,939,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Trading Up 1.7%

Shares of Cooper Companies stock opened at $59.12 on Wednesday. The Cooper Companies, Inc. has a fifty-two week low of $51.01 and a fifty-two week high of $89.83. The firm has a market cap of $11.24 billion, a PE ratio of 20.18, a P/E/G ratio of 2.37 and a beta of 0.83. The business’s fifty day moving average is $62.74 and its two-hundred day moving average is $65.94. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the prior year, the business posted $0.49 earnings per share. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Analysts anticipate that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies declared that its Board of Directors has authorized a stock repurchase program on Wednesday, September 9th that permits the company to buy back $3.00 billion in shares. This repurchase authorization permits the medical device company to purchase up to 22.7% of its stock through open market purchases. Share repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

COO has been the subject of several recent research reports. William Blair downgraded Cooper Companies from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 10th. UBS Group reduced their price objective on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a research report on Thursday, September 10th. Mizuho set a $75.00 price objective on Cooper Companies and gave the company an “outperform” rating in a research report on Thursday, September 10th. Stifel Nicolaus set a $70.00 price objective on Cooper Companies and gave the company a “buy” rating in a research note on Thursday, September 10th. Finally, JPMorgan Chase & Co. dropped their price objective on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating for the company in a research report on Thursday, September 10th. Four analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Cooper Companies currently has a consensus rating of “Hold” and an average price target of $68.60.

Insider Activity

In related news, Director Lawrence Kurzius purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was purchased at an average price of $53.91 per share, with a total value of $539,100.00. Following the completion of the transaction, the director owned 21,099 shares of the company’s stock, valued at approximately $1,137,447.09. This trade represents a 90.10% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Paul Keel purchased 4,701 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was bought at an average price of $53.18 per share, for a total transaction of $249,999.18. Following the acquisition, the director owned 4,701 shares in the company, valued at $249,999.18. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 34,701 shares of company stock valued at $1,880,039 in the last 90 days. 2.08% of the stock is currently owned by insiders.

Cooper Companies Company Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.